These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

618 related articles for article (PubMed ID: 18309481)

  • 1. Differentiation between malignant and benign pathologic fractures with F-18-fluoro-2-deoxy-D-glucose positron emission tomography/computed tomography.
    Shin DS; Shon OJ; Byun SJ; Choi JH; Chun KA; Cho IH
    Skeletal Radiol; 2008 May; 37(5):415-21. PubMed ID: 18309481
    [TBL] [Abstract][Full Text] [Related]  

  • 2. More advantages in detecting bone and soft tissue metastases from prostate cancer using
    Pianou NK; Stavrou PZ; Vlontzou E; Rondogianni P; Exarhos DN; Datseris IE
    Hell J Nucl Med; 2019; 22(1):6-9. PubMed ID: 30843003
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The clinical efficacy of (18)F-FDG-PET/CT in benign and malignant musculoskeletal tumors.
    Shin DS; Shon OJ; Han DS; Choi JH; Chun KA; Cho IH
    Ann Nucl Med; 2008 Aug; 22(7):603-9. PubMed ID: 18756363
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Role of ¹⁸F-FDG PET/CT in differentiation of a benign lesion and metastasis on the ribs of cancer patients.
    Choi HS; Yoo IeR; Park HL; Choi EK; Kim SH; Lee WH
    Clin Imaging; 2014; 38(2):109-14. PubMed ID: 24361174
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Value of dual-time-point (18)F-fluorodeoxyglucose integrated positron emission and computed tomography in differentiation of malignant from benign gastrointestinal diseases].
    Xu XX; Cheng J; Xu WG; Dai D; Song XY; Ma WC; Zhu L; Zhu X
    Zhonghua Zhong Liu Za Zhi; 2012 May; 34(5):364-8. PubMed ID: 22883458
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The role of fluorodeoxyglucose-positron emission tomography/computed tomography in differentiating between benign and malignant adrenal lesions.
    Ozcan Kara P; Kara T; Kara Gedik G; Kara F; Sahin O; Ceylan Gunay E; Sari O
    Nucl Med Commun; 2011 Feb; 32(2):106-12. PubMed ID: 21085046
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The value of prebiopsy FDG-PET/CT in discriminating malignant from benign vertebral bone lesions in a predominantly oncologic population.
    Loudini N; Glaudemans AWJM; Jutte PC; Yakar D; Kwee TC
    Skeletal Radiol; 2020 Sep; 49(9):1387-1395. PubMed ID: 32253470
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Dual-time point PET/CT with F-18 FDG for the differentiation of malignant and benign bone lesions.
    Tian R; Su M; Tian Y; Li F; Li L; Kuang A; Zeng J
    Skeletal Radiol; 2009 May; 38(5):451-8. PubMed ID: 19205695
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The value of dual time point (18)F-FDG PET imaging for the differentiation between malignant and benign lesions.
    Lan XL; Zhang YX; Wu ZJ; Jia Q; Wei H; Gao ZR
    Clin Radiol; 2008 Jul; 63(7):756-64. PubMed ID: 18555033
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Role of (18)F-fluorodeoxyglucose positron emission tomography/computed tomography in the characterization of pancreatic masses: experience from tropics.
    Santhosh S; Mittal BR; Bhasin D; Srinivasan R; Rana S; Das A; Nada R; Bhattacharya A; Gupta R; Kapoor R
    J Gastroenterol Hepatol; 2013 Feb; 28(2):255-61. PubMed ID: 23278193
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Texture analysis on (18)F-FDG PET/CT images to differentiate malignant and benign bone and soft-tissue lesions.
    Xu R; Kido S; Suga K; Hirano Y; Tachibana R; Muramatsu K; Chagawa K; Tanaka S
    Ann Nucl Med; 2014 Nov; 28(9):926-35. PubMed ID: 25107363
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Evaluation of soft-tissue lesions with (18)F-FDG PET/CT: initial results of a prospective trial.
    Leal AL; Etchebehere M; Santos AO; Kalaf G; Pacheco EB; Amstalden EM; Etchebehere EC
    Nucl Med Commun; 2014 Mar; 35(3):252-9. PubMed ID: 24300379
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The prevalence and clinical significance of (18) F-2-fluoro-2-deoxy-D-glucose (FDG) uptake in the thyroid gland on PET or PET-CT in patients with lymphoma.
    Lin M; Wong C; Lin P; Shon IH; Cuganesan R; Som S
    Hematol Oncol; 2011 Jun; 29(2):67-74. PubMed ID: 20635328
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Differential diagnostic value of
    He X; Zhao L; Guo X; Zhao L; Wu J; Huang J; Sun L; Xie C; Chen H
    Cancer Manag Res; 2018; 10():2105-2115. PubMed ID: 30050321
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Impact of maximum standardized uptake value (SUVmax) evaluated by 18-Fluoro-2-deoxy-D-glucose positron emission tomography/computed tomography (18F-FDG-PET/CT) on survival for patients with advanced renal cell carcinoma: a preliminary report.
    Namura K; Minamimoto R; Yao M; Makiyama K; Murakami T; Sano F; Hayashi N; Tateishi U; Ishigaki H; Kishida T; Miura T; Kobayashi K; Noguchi S; Inoue T; Kubota Y; Nakaigawa N
    BMC Cancer; 2010 Dec; 10():667. PubMed ID: 21129184
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Utility of FDG-PET in differential diagnosis of benign and malignant fractures in acute to subacute phase.
    Kato K; Aoki J; Endo K
    Ann Nucl Med; 2003 Feb; 17(1):41-6. PubMed ID: 12691129
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Differentiation of soft tissue and bone sarcomas from benign lesions utilizing
    Chen B; Feng H; Xie J; Li C; Zhang Y; Wang S
    BMC Med Imaging; 2020 Jul; 20(1):85. PubMed ID: 32711449
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Bone marrow 18F-fluoro-2-deoxy-D-glucose positron emission tomography/computed tomography cannot replace bone marrow biopsy in diffuse large B-cell lymphoma.
    Adams HJ; Kwee TC; Fijnheer R; Dubois SV; Nievelstein RA; de Klerk JM
    Am J Hematol; 2014 Jul; 89(7):726-31. PubMed ID: 24711255
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Hyperaccumulation of (18)F-FDG in order to differentiate solid pseudopapillary tumors from adenocarcinomas and from neuroendocrine pancreatic tumors and review of the literature.
    Guan ZW; Xu BX; Wang RM; Sun L; Tian JH
    Hell J Nucl Med; 2013; 16(2):97-102. PubMed ID: 23687644
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Utility of 2-[18F] fluoro-2-deoxy-D-glucose positron emission tomography in differential diagnosis of benign and malignant intraductal papillary-mucinous neoplasm of the pancreas.
    Tomimaru Y; Takeda Y; Tatsumi M; Kim T; Kobayashi S; Marubashi S; Eguchi H; Tanemura M; Kitagawa T; Nagano H; Umeshita K; Wakasa K; Doki Y; Mori M
    Oncol Rep; 2010 Sep; 24(3):613-20. PubMed ID: 20664965
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 31.